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In the postnatal mammalian brain, stem cells in the ventricular-subventricular zone (V-SVZ)
continuously generate neuronal and glial cells throughout life. Genetic labeling of cells
of specific lineages have demonstrated that the V-SVZ is an important source of the
neuroblasts and/or oligodendrocyte progenitor cells (OPCs) that migrate toward injured
brain areas in response to several types of insult, including ischemia and demyelinating
diseases. However, this spontaneous regeneration is insufficient for complete structural
and functional restoration of the injured brain, so interventions to enhance these
processes are sought for clinical applications. Erythropoietin (EPO), a clinically applied
erythropoietic factor, is reported to have cytoprotective effects in various kinds of insult
in the central nervous system. Moreover, recent studies suggest that EPO promotes the
V-SVZ-derived neurogenesis and oligodendrogenesis. EPO increases the proliferation of
progenitors in the V-SVZ and/or the migration and differentiation of their progenies in and
around injured areas, depending on the dosage, timing, and duration of treatment, as well
as the type of animal model used. On the other hand, EPO has undesirable side effects,
including thrombotic complications. We recently demonstrated that a 2-week treatment
with the EPO derivative asialo-EPO promotes the differentiation of V-SVZ-derived OPCs
into myelin-forming mature oligodendrocytes in the injured white matter of neonatal mice
without causing erythropoiesis. Here we present an overview of the multifaceted effects
of EPO and its derivatives in the V-SVZ and discuss the possible applications of these
molecules in regenerative medicine.
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PRODUCTION OF NEURONAL AND OLIGODENDROCYTE
PROGENITORS IN THE V-SVZ
NEW NEURON PRODUCTION IN THE V-SVZ
Neural stem cells (NSCs) in the ventricular-subventricular zone
(V-SVZ), located at the lateral walls of the lateral ventricles,
have been investigated as an endogenous cell source for neu-
rons (Belvindrah et al., 2009; Kriegstein and Alvarez-Buylla,
2009; Ihrie and Alvarez-Buylla, 2011; Ming and Song, 2011)
and oligodendrocytes (Nait-Oumesmar et al., 2008; Gonzalez-
Perez and Alvarez-Buylla, 2011) in the postnatal brain. While
maintaining themselves by self-renewing cell division, the NSCs
produce actively proliferating intermediate progenitors called
transit-amplifying cells, which generate immature new neurons,
called neuroblasts. The neuroblasts born in the V-SVZ are char-
acterized by their prominent migration capacity. They have a
bipolar shape with leading and trailing processes, and in the ros-
tral migratory stream, they migrate in chain-like aggregates for a
long distance to the olfactory bulb, where they differentiate into
interneurons to be integrated into the olfactory circuitry (Luskin,
1993; Lois and Alvarez-Buylla, 1994; Petreanu and Alvarez-Buylla,
2002; Carleton et al., 2003).
These neurogenic cells are tightly associated with the vascu-
lature. NSCs extend their process with an endfoot that makes
contact with blood vessels (Mirzadeh et al., 2008; Tavazoie et al.,
2008), the transit-amplifying progenitors reside very close to ves-
sels (Shen et al., 2008; Tavazoie et al., 2008; Kokovay et al., 2010),
and the neuroblasts frequently migrate along vessels (Snapyan
et al., 2009; Whitman et al., 2009). Therefore, although its precise
function remains unclear, the vasculature is thought to contribute
to the neurogenic function of the progenitor cells and the efficient
migration of neuroblasts (Ihrie and Alvarez-Buylla, 2011).
OLIGODENDROCYTE PRODUCTION IN THE V-SVZ
Oligodendrocytes form the myelin sheath, which wraps around
axons to facilitate the rapid, saltatory conduction of electrical
impulses along them. In early postnatal stages, V-SVZ is an
important source of forebrain oligodendrocyte progenitor cells
(OPCs) (Levison and Goldman, 1993; Luskin, 1993; Ivanova
et al., 2003; Suzuki andGoldman, 2003). These OPCs differentiate
into mature oligodendrocytes after they migrate to and colonize
the parenchyma. However, a portion of the OPCs remain as pro-
genitors, which are called NG2 glia due to their expression of the
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OPC marker NG2 proteoglycan, and become a major provider of
oligodendrocytes in later postnatal stages and throughout adult-
hood. (Stallcup and Beasley, 1987; Gensert and Goldman, 1997;
Nishiyama et al., 2002; Greenwood and Butt, 2003; Fancy et al.,
2004).
Recent studies revealed that the adult V-SVZ continuously
produces OPCs, via a distinct group of transit-amplifying progen-
itors that express the oligodendrocyte lineage markers Olig2 and
NG2 (Levison and Goldman, 1993; Nait-Oumesmar et al., 1999;
Picard-Riera et al., 2002; Hack et al., 2005; Menn et al., 2006).
Although the adult V-SVZ-derived OPCs are a minor population
among the entire OPC pool in the brain, they have a distinctive
capacity to migrate actively over long distances into the corpus
callosum, striatum, and fimbria fornix, where they differentiate
into mature, myelin-forming oligodendrocytes (Nait-Oumesmar
et al., 1999; Menn et al., 2006; Aguirre et al., 2007). Like the
migrating neuroblasts, the migrating OPCs have a bipolar mor-
phology with leading and trailing processes, however, they tend to
migrate individually rather than by forming chain-like aggregates
(Menn et al., 2006).
NEUROGENESIS AND OLIGODENDROGENESIS UNDER PATHOLOGICAL
CONDITIONS
Cell proliferation in the V-SVZ is up-regulated in response to
various pathological conditions that cause neuronal loss, such as
ischemic stroke and neurodegenerative diseases. The neuroblasts
generated in the V-SVZ migrate toward the injured area and dif-
ferentiate into functional mature neurons (Yamashita et al., 2006;
Kojima et al., 2010; Yoshikawa et al., 2010).
Myelin degeneration blocks conduction, whether it occurs
in the context of oligodendrocyte-specific disorders, such as
multiple sclerosis, or as a result of non-specific insults, includ-
ing severe ischemia. The blocked conduction induces a vari-
ety of neurological impairments. After demyelination, new
oligodendrocytes generated from the parenchymal OPCs con-
tribute to remyelination (Reynolds et al., 2002; Aguirre et al.,
2007; Fancy et al., 2009, 2011; Patel et al., 2010; Azim and
Butt, 2011; Huang et al., 2011; Mi et al., 2011). In addi-
tion, in the brains of multiple sclerosis patients and of rodent
demyelination models, new OPC production in the V-SVZ
is significantly increased, and these OPCs also contribute to
remyelination (Nait-Oumesmar et al., 1999, 2007). Furthermore,
V-SVZ-derived migrating progenitors committed to the neu-
ronal lineage can apparently change their fate to differentiate
into oligodendrocytes in demyelinated areas (Jablonska et al.,
2010).
The insult-induced spontaneous regeneration of neurons and
oligodendrocytes is insufficient for full structural and func-
tional restoration of the injured brain. Therefore, interven-
tions to enhance these processes are being sought for future
clinical applications. Various interventions that increase new
neurons/oligodendrocytes have already been shown to improve
neurological function (Leker et al., 2009; Lindvall and Kokaia,
2010; Nakaguchi et al., 2011; Christie and Turnley, 2012).
Erythropoietin (EPO), a clinically used erythropoietic factor, is
one of the promising candidate drugs that promote V-SVZ-
derived neurogenesis and oligodendrogenesis.
ENDOGENOUS EPO ACTIVITY IN THE CENTRAL NERVOUS
SYSTEM (CNS)
EPO AND ITS RECEPTOR
EPO is a single polypeptide glycoprotein hormone that is mainly
produced in and secreted from fetal hepatocytes and interstitial
fibroblasts in the adult kidney, to increase the number of circu-
lating erythrocytes (Marti, 2004). It consists of 166 amino acids
folded into 4 α-helices, and includes three N-glycosylation sites
that each accommodate up to four sialic acid residues (Jacobs
et al., 1985; Lin et al., 1985; Lai et al., 1986). The sialylation
contributes to EPO’s stability in the circulation (Fukuda et al.,
1989).
EPO production dramatically increases in response to low
partial oxygen pressure, mediated by the activation of hypoxia-
inducible factor (Franke et al., 2013). In addition to hypoxia,
metabolic stress, or proinflammatory cytokines can induce EPO
production (Maiese et al., 2012). Upon binding to the homod-
imeric EPO receptor (EPOR) on erythroid progenitors in bone
marrow (Marti, 2004), EPO induces JAK2 phosphorylation and
the activation of downstream signaling pathways, including
STAT5, PI3K/Akt, and MAPK, which enhance the proliferation,
differentiation, and survival of the progenitors, thereby increasing
the number of circulating erythrocytes (Quelle et al., 1996; Zhao
et al., 2006). Cloned in 1985 (Jacobs et al., 1985; Lin et al., 1985),
recombinant human EPO (rhEPO) has been used as a treatment
for anemia (mainly caused by chronic renal failure) for more than
20 years.
EPO AND EPOR IN THE CNS
After EPO’s hematopoietic functions were reported, subsequent
studies have indicated that EPO is produced in other adult organs
in addition to the kidney, such as the liver, spleen, and CNS,
in response to hypoxia (Marti, 2004; Chateauvieux et al., 2011;
Lombardero et al., 2011). The expression of EPO and EPOR in
the brain is reported in rodents, monkeys, and humans during
development and in adulthood (Marti et al., 1996; Juul et al.,
1998; Knabe et al., 2004), and especially in the periventricular ger-
minal zone of the fetal brain (Liu et al., 1997; Juul et al., 1999;
Tsai et al., 2006). Although their expression decreases dramati-
cally during the course of development, EPO and EPOR continue
to be expressed in the adult V-SVZ (Liu et al., 1997).
Astrocytes were the first cells to be identified as EPO pro-
ducers in the brain (Masuda et al., 1994; Marti et al., 1996).
Later, neurons in several regions were also found to produce
EPO (Bernaudin et al., 1999, 2000; Siren et al., 2001). Although
much less EPO is produced in the brain than in the kid-
ney (Tan et al., 1992), the locally produced EPO might play
an important role in the brain, because EPO in the periphery
cannot efficiently cross the blood-brain barrier (BBB) via lipid-
mediated transport under normal conditions, due to its large
molecular size.
Intriguingly, compared to the EPO in the circulation, brain-
derived EPO has less sialylation, and consequently exhibits a
smaller molecular weight and shorter plasma half-life, but it has
a higher affinity for EPOR (Masuda et al., 1994). EPO produc-
tion in the brain is induced by hypoxia, although the time course
is quite different from that in the periphery. During hypoxia
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exposure, the brain EPO mRNA level rises rapidly, and this
increased level is sustained for more than 24 h, whereas the circu-
lating EPO protein and EPOmRNA in the kidney quickly decline
to basal levels even under conditions of continuous hypoxia
(Chikuma et al., 2000). Taken together, these findings indicate
that EPO in the brain has a distinct bioactivity and regulatory
system from that in the circulation.
EPOR is also expressed in various cell types in the brain,
including neurons, astrocytes, OPCs, microglia, and endothelial
cells (Brines et al., 2000; Nagai et al., 2001; Sugawa et al., 2002;
Marti, 2004). EPOR’s expression is induced by hypoxia (Chin
et al., 2000; Yu et al., 2002), proinflammatory cytokines (Nagai
et al., 2001), and EPO (Chin et al., 2000), and its distribution cor-
responds to that of EPO, suggesting that brain EPO works in a
paracrine/autocrine manner in response to hypoxia. In neuronal
cells, in addition to the STAT5, PI3K/Akt, and MAPK pathways,
NF-κB is involved in EPO-EPOR signaling (Digicaylioglu and
Lipton, 2001; Yu et al., 2002).
FUNCTION OF ENDOGENOUS EPO SIGNALING IN THE BRAIN
While a lack of EPO-EPOR signaling causes embryonic lethality
with severe anemia (Wu et al., 1995; Lin et al., 1996), the brain-
specific knockout of EPOR from the late embryonic phase (using
EPOR-floxed mice crossed with human GFAP-Cre mice) and
selective EPOR knock-in in the hematopoietic tissues of EPOR-
null mice cause only a small defect in brain development (Suzuki
et al., 2002; Tsai et al., 2006; Chen et al., 2007), suggesting that
EPO signaling is not deeply associated with brain development.
However, interestingly, EPOR is expressed in nestin-expressing
NSCs in the ganglionic eminence, including in the area that
develops into the postnatal V-SVZ, and hypoxia-induced EPO
expression in NSCs in vitro promotes neuronal differentiation
(Shingo et al., 2001). EPOR is also expressed in EGFR-expressing
neuronal progenitors (mostly transit-amplifying progenitors) in
the adult V-SVZ. In an ischemic stroke model, brain-specific
EPOR knockdown did not affect the infarct volume, but it sup-
pressed reactive cell proliferation in the V-SVZ and the migration
of neuroblasts to the injury site (Tsai et al., 2006). These find-
ings indicated that endogenous EPO-EPOR signaling in the brain
is involved in controlling neurogenesis under physiological and
pathological conditions.
CNS PROTECTION BY EPO TREATMENT
PROTECTIVE EFFECTS OF EPO ON NEURONS AND OLIGODENDROCYTES
A number of studies have revealed beneficial effects of EPO
administration in various animal models for CNS diseases
(Ghezzi and Brines, 2004; Maiese et al., 2004; van der Kooij
et al., 2008) and in patients with ischemic stroke, schizophrenia,
and multiple sclerosis (Siren et al., 2009). Recombinant human
EPO (rhEPO) treatment directly protects neurons from hypoxia,
excitotoxins, and metabolic stresses in vitro through multiple
pathways, such as by blocking calcium influx-induced glutamate
release, enhancing anti-apoptotic and anti-oxidant protein pro-
duction, and suppressing pro-apoptotic protein and free radial
production (Ghezzi and Brines, 2004; Marti, 2004; van der Kooij
et al., 2008; Maiese et al., 2012). The peripheral administration or
intraventricular infusion of rhEPO protects neurons in a number
of experimental disease models, including those for ischemic
stroke, traumatic injury, neurodegenerative diseases, seizure, and
schizophrenia, by modifying the immune reaction and degree
of inflammation, protecting the BBB, promoting angiogenesis to
restore the oxygen supply, and suppressing brain atrophy and
secondary gliosis, in addition to EPO’s direct neuroprotective
activities (Ghezzi and Brines, 2004; Maiese et al., 2004; Noguchi
et al., 2007; van der Kooij et al., 2008; Chateauvieux et al., 2011).
rhEPO treatment also protects oligodendrocytes and OPCs
and prevents demyelination in animal models of multiple scle-
rosis, spinal cord injury, and stroke (Zhang et al., 2005; Savino
et al., 2006; Vitellaro-Zuccarello et al., 2007; Mizuno et al., 2008).
While several studies support the finding that EPOR is expressed
onOPCs (Nagai et al., 2001; Sugawa et al., 2002; Kato et al., 2011),
whether or not it is expressed on mature oligodendrocytes is
still controversial. It is possible that EPO stimulates other EPOR-
expressing cell type(s), thereby indirectly promoting the survival
of oligodendrocytes.
With regard to how peripherally administered EPO reaches the
brain, both receptor-mediated active transport and extracellular
pathways are used to pass EPO through the BBB (Brines et al.,
2000; Banks et al., 2004; Ehrenreich et al., 2004; Juul et al., 2004;
Xenocostas et al., 2005). After a single high-dose intravenous
injection, EPO is detectable in the brain within hours, reach-
ing a peak concentration at 3–4 h in the brain or cerebrospinal
fluid in humans and other animals (Banks et al., 2004; Ehrenreich
et al., 2004; Juul et al., 2004; Xenocostas et al., 2005). Although the
influx of EPO is restricted in the healthy brain, the permeability of
the BBB is significantly increased by brain insults such as ischemic
stroke (Yang and Rosenberg, 2011), which can increase the ability
of peripherally administered EPO to cross into the brain.
RECEPTORS FOR EPO IN CYTOPROTECTION
In addition to the homodimeric EPOR, EPO binds to a het-
erodimeric receptor consisting of the classical EPOR and the beta
common receptor (βcR), a subunit also known as CD131 and
shared by several cytokine receptors, including those for inter-
leukin (IL)-3, IL-5, and granulocyte-macrophage colony stimu-
lating factor (Hanazono et al., 1995; Jubinsky et al., 1997). While
the hematopoietic activity of EPO depends on the homodimeric
EPOR, other effects appear to be mediated by the heterodimeric
receptor, which has a lower affinity for EPO. For example, EPO
does not exert its protective effect on spinal cord injury in mice
lacking βcR (Brines et al., 2004). Moreover, EPO derivatives that
do not bind the homodimeric EPOR can still protect tissue and
improve neurological function similarly to EPO in stroke, spinal
cord injury, and demyelination models (Brines et al., 2004; Leist
et al., 2004; Savino et al., 2006; King et al., 2007; Villa et al., 2007;
Wang et al., 2007b), indicating that the tissue-protection function
of EPO might be mediated by the βcR-containing heterodimeric
receptor.
On the other hand, the expression level of βcR in the brain
is relatively quite low, and its localization does not correspond
to the expression of EPO/EPOR or to the cell types protected by
EPO treatment in culture or in a pilocarpine-induced epilepsy
model (Nadam et al., 2007; Um et al., 2007; Sanchez et al., 2009).
EPO inhibits apoptosis in neuron-like cell lines in which the βcR
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expression is undetectable, and the interaction between EPO and
homodimeric EPOR appears to be essential for this effect (Um
et al., 2007). These data suggest that EPO needs to interact with
classical homodimeric EPOR to exert its neuroprotective effect.
However, the functional difference between the homodimeric and
heterodimeric EPOR in the V-SVZ has not been demonstrated.
DERIVATIVES OF EPO USED FOR CYTOPROTECTIVE TREATMENT
Many derivatives of EPO have a cytoprotective effect similar to
that of EPO itself (Jerndal et al., 2010). Daberpoetin-alpha, an
EPO derivative with 3 times the circulation half-life of endoge-
nous EPO, due to having more sialic acid moieties, is not only
beneficial for treating anemia, but also has a neuroprotective
activity similar to that of EPO in stroke, intracerebral hemor-
rhage, and acute ethanol intoxication models (Seymen et al.,
2013; Belayev et al., 2005; Grasso et al., 2009). On the other hand,
the hematopoietic activity of EPO and its derivatives sometimes
causes polycythemia and thrombosis, making them inappropri-
ate for clinical use to treat CNS disorders. Therefore, the effect
of derivatives with reduced or no hematopoietic activity has been
investigated in several diseasemodels (Leist et al., 2004; Villa et al.,
2007).
Asialo erythropoietin (AEPO), which is generated by the total
enzymatic desialylation of rhEPO, binds to the homodimeric
EPOR with a similar affinity as EPO, but is rapidly cleared from
the circulation by hepatic cells, due to the lack of sialic acid at
the terminals of its oligosaccharides (plasma half life, EPO: 5.6 h,
AEPO: 1.4min by intravenous administration) (Fukuda et al.,
1989; Imai et al., 1990). Notably, in vitro experiments revealed
that, while the induction of hematopoiesis requires EPO stimu-
lation of long duration, only 5min of EPO exposure is sufficient
for neuroprotection (Morishita et al., 1997). We and others fur-
ther revealed that repeated AEPO administration biweekly for
more than 1 month in adult mice (Erbayraktar et al., 2003) or
once a day for 2 consecutive weeks in neonatal mice (Kako et al.,
2012) did not enhance erythropoiesis. Nevertheless, AEPO pro-
tects neurons (Erbayraktar et al., 2003; Wang et al., 2004b; Grasso
et al., 2006) and oligodendrocytes (Savino et al., 2006) in stroke,
spinal cord injury, sciatic nerve injury, and multiple sclerosis
models. Since AEPO is a natural physiological metabolite of EPO,
it appears to be a promising and safe drug for clinical applications.
Carbamylated erythropoietin (CEPO) is a derivative produced
by chemically replacing all the lysine residues in EPO with
homocitruline, a process called carbamylation. CEPO has a sim-
ilar plasma half-life as EPO. Although CEPO does not bind
to homodimeric EPOR, which is responsible for EPO-induced
hematopoiesis (Leist et al., 2004), CEPO treatment protects neu-
rons and oligodendrocytes from apoptosis, and it protects tissue
and suppresses inflammation in brain and spinal cord injury
models and cultures, as effectively as EPO (Brines et al., 2004;
Leist et al., 2004; Montero et al., 2007; Villa et al., 2007; Wang
et al., 2007b; Liu et al., 2011; Xiong et al., 2011). CEPO can bind
to the EPOR and βcR heterodimeric receptor, and this binding
was reported to mediate CEPO’s cytoprotective effect in spinal
cord injury (Brines et al., 2004). However, because CEPO is not
a natural metabolite, careful investigation is needed to evaluate
its safety for clinical applications.
PROMOTION OF NEUROGENESIS/OLIGODENDROGENESIS IN
THE V-SVZ BY EPO TREATMENT
While most previous studies suggest that EPO and its deriva-
tives should be administered before or immediately after injury
to elicit their tissue-protective effects in various animal mod-
els (van der Kooij et al., 2008), delaying administration for 24 h
or even for several days after the insult can enhance neuro-
genesis and/or oligodendrogenesis, and lead to improved neu-
rological symptoms weeks to months after the insult (Wang
et al., 2004a; Iwai et al., 2010; Zhang et al., 2010; Kako et al.,
2012) (Table 1). Although the functional aspects of the new neu-
rons/oligodendrocytes are still unclear, infusion of an anti-mitotic
agent, Ara-C, which inhibits neurogenesis, effectively abolished
the functional recovery after EPO treatment in a traumatic injury
model (Zhang et al., 2012), suggesting that the EPO-induced
functional improvement depends, at least in part, on the produc-
tion of new neurons/oligodendrocytes after the injury.
PROMOTION OF NEUROGENESIS BY EPO TREATMENT
rhEPO administration promotes neurogenesis under both phys-
iological and pathological conditions. In the intact brain, rhEPO
infusion for 6 days into the lateral ventricle increases the num-
ber of neuronal progenitor cells, with a concomitant decrease
in the number of NSCs, suggesting that EPO enhances neu-
ronal differentiation (Shingo et al., 2001). Furthermore, in stroke
and neonatal hypoxia/ischemia models, peripherally adminis-
tered rhEPO increases the numbers of both NSCs and neuronal
progenitors by promoting their proliferation and neuronal dif-
ferentiation, and it enhances the migration of neuroblasts to the
injury site (Wang et al., 2004a; Iwai et al., 2007). The intraven-
tricular infusion of rhEPO in 6-OH-DOPA-injected Parkinson’s
disease model animals also enhances neuroblast production in
the V-SVZ and increases the number of neuroblasts within the
striatum (Kadota et al., 2009).
With regard to how EPO affects neurogenesis, in vitro studies
suggest that it has direct effects on NSCs. For example, in NSCs
dissociated from the adult V-SVZ, EPO treatment increases Akt
activity, which promotes proliferation, differentiation, and neu-
rite outgrowth; neurogenin-1 is involved in this pathway (Wang
et al., 2006b). In a similar culture system, CEPO activates sonic
hedgehog to induce the expression of Mash1, a bHLH transcrip-
tion factor that increases neurogenesis (Wang et al., 2007a). In
embryonic NSCs, EPO enhances the nuclear translocation of
NF-κB to promote neuronal differentiation and induces Mash1
expression (Shingo et al., 2001).
EPO can also enhance neurogenesis through the protection
and remodeling of the cerebral vasculature. As previously men-
tioned, the vasculature is involved in maintaining the function
of NSCs and transit-amplifying neuronal progenitors in the
V-SVZ. In addition, after ischemia, endothelial cells secrete attrac-
tive molecules such as SDF-1 and angiopoietin-1, which guide
neuroblasts expressing receptors for these molecules toward the
injury (Imitola et al., 2004; Ohab et al., 2006; Robin et al., 2006).
Blood vessels also appear to act as a scaffold for the migrating
neuroblasts in the striatum after stroke (Yamashita et al., 2006;
Kojima et al., 2010) and for V-SVZ-derived progenitors that give
rise to oligodendrocytes in the demyelinated corpus callosum
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Table 1 | EPO’s effects on V-SVZ neurogenesis/oligodendrogenesis.
Model Age EPO treatment Effects on neurogenesis, oligodendrogenesis, and
angiogenesis
References
Rat,
stroke
Adult rhEPO, i.p., 1-8 dpi V-SVZ: increase in NSCs and neuroblasts
St, Cx: increase in neuroblasts and blood vessels
Wang et al., 2004a, 2006a
Rat,
stroke
Adult rhEPO, i.p.,
0-4 dpi
V-SVZ: increase in cell proliferation and OPCs
Cx: increase in angiogenesis
Kim and Jung, 2010
Rat,
stroke
Adult rhEPO, i.p.,
1-8 dpi
(Lentivirus injection into V-SVZ 3 d before injury)
V-SVZ: increase in OPCs and OPC proliferation
St: increase in virus-labeled OPCs
Zhang et al., 2010
Mouse,
stroke
Adult rhEPO, with hydrogel,
epicortical,
4 or 11 dpi
V-SVZ: increase in neuroblasts
St, Cx: increase in neuroblasts
Wang et al., 2012
Rat,
stroke
Neonate
(P 10)
rhEPO, i.p.
0 dpi
St: increase in mature new neurons Gonzalez et al., 2007
Rat,
stroke
Neonate
(P 7)
rhEPO, i.p.
0, 1, 7 dpi
(Lentivirus injection into LV at P1)
St, Cx: increase in virus-labeled neuroblasts and OPCs, decrease
in virus-labeled astrocytes
Gonzalez et al., 2013
Rat,
H/I
Neonate
(P 7)
rhEPO, i.p.
0, 2, 4, 6 dpi
V-SVZ: increase in proliferating cells and neuroblasts
St, Cx: increase in neuroblasts, mature new neurons, and blood
vessels
Iwai et al., 2007
Rat,
H/I
Neonate
(P 7)
rhEPO, i.p.
2, 4, 6, 9, 13 dpi
St, Cx: increase in neuroblasts
St, Cx, CC: increase in OPCs and oligodendrocytes
Cx, CC: increase in BrdU-labeled oligodendrocytes
Iwai et al., 2010
Mouse,
H/I
Neonate
(P 9)
rhEPO, i.p.
0, 1, 2 dpi
V-SVZ: increase in proliferating cells (only in females) Fan et al., 2011
Mouse,
H/I
Neonate
(P 5)
AEPO, i.p.,5-19 dpi (Retrovirus injection into V-SVZ at P5)
CC: promotion of oligodendrocyte differentiation
Kako et al., 2012
Rat,
6-OHDA
Adult rhEPO, i.c.v. for 7 d V-SVZ: increase in neuroblast
St: increase in neuroblasts
Kadota et al., 2009
Mouse,
intact
Adult rhEPO, i.c.v.,
for 6 d
V-SVZ: decrease in NSCs, increase in NPCs and neuroblasts Shingo et al., 2001
Mouse,
intact
Adult EPOR-CKO V-SVZ: decrease in cell proliferation Tsai et al., 2006
Mouse,
stroke
Adult EPOR-CKO V-SVZ: lack of stroke-induced increase in cell proliferation Tsai et al., 2006
Mouse,
intact
Adult Conditionally rescued
EPOR−/−
V-SVZ: decrease in cell-proliferation Chen et al., 2007
Previous studies that report the effects of EPO treatment and EPO signaling modification on V-SVZ-associated neurogenesis and oligodendrogenesis. i.c.v.,
intracerebroventricular; i.p., intraperitoneal; dpi, days post injury; St, striatum; Cx, cortex; P, postnatal day; H/I, hypoxia/ischemia; CKO, conditional knockout.
(Cayre et al., 2013). EPO treatment suppresses the apoptosis of
vascular endothelial cells in which EPOR expression is strongly
induced by ischemia (Bernaudin et al., 1999; Chong et al., 2002),
and promotes angiogenesis to restore blood flow in the ischemic
area (Li et al., 2007). This angiogenesis is reported to be mediated
by the enhanced endothelial expression of VEGF, a critical growth
factor for generating and remodeling the vasculature (Wang et al.,
2004a). EPO also inducesmatrixmetalloproteinase (MMP)-2 and
MMP-9 in endothelial cells, via activation of the Akt and ERK1/2
pathway, to promote neuroblast migration (Wang et al., 2006a).
Interestingly, EPO-treated neurospheres derived from the adult
V-SVZ promote the capillary-like tube formation of cultured
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endothelial cells by secreting VEGF (Wang et al., 2008). Therefore,
EPO’s efficient enhancement of neurogenesis and oligodendroge-
nesis appears to be tightly associated with vascular function.
PROMOTION OF OLIGODENDROGENESIS BY EPO TREATMENT
In addition to preventingmyelin degeneration (Zhang et al., 2005;
Savino et al., 2006; Vitellaro-Zuccarello et al., 2007; Liu et al.,
2011), several studies have reported that delaying EPO treatment
by 1–7 days after the insult, which doesn’t protect the tissue
from injury, efficiently enhances the production of new oligo-
dendrocytes (Iwai et al., 2010; Zhang et al., 2010; Kako et al.,
2012) and promotes white matter reorganization (Li et al., 2009)
leading to improved neurological function. While the underlying
mechanism remains unknown, these observations suggest that
EPO treatment promotes remyelination to alleviate neurological
dysfunction.
Since oligodendrogenesis takes place not only in localized
areas, but also widely throughout the brain even in adulthood,
especially after demyelination, a region-specific cellular label-
ing method is needed to determine the effect of EPO treat-
ment on the behavior of V-SVZ-derived OPCs/oligodendrocytes.
For this purpose, viral vectors were stereotaxically injected into
the rodent V-SVZ (Zhang et al., 2010; Kako et al., 2012).
The lentivirus vector is efficiently integrated into the genome
of both proliferating and non-proliferating cells, permanently
labeling them and their progenies. Using this system, a 7-day
treatment with EPO starting 24 h after ischemic stroke was
shown to increase the OPCs in the V-SVZ, and to promote
the recruitment to the injury site of lentivirus-labeled cells that
express a mature oligodendrocyte marker (Zhang et al., 2010).
In addition, in a neonatal stroke model, EPO treatment was
shown to promote the proliferation of lentivirus-labeled NSCs,
which preferentially produced neurons and oligodendrocytes
rather than astrocytes in the injured striatum (Gonzalez et al.,
2013).
To investigate the specific effect of EPO treatment on
V-SVZ-derived OPCs, we combined a retrovirus injection into
the V-SVZ (which labels proliferating cells and their progenies)
with a lineage-specific fate-mapping method for OPCs, using
tamoxifen-induced recombination, in a neonatal ischemic injury
model (Kako et al., 2012). Even though V-SVZ-derived OPCs
showed extensive migration in the corpus callosum toward the
injured white matter, only about 30% of them underwent mat-
uration in the subsequent 19 days. The maturation ratio was
significantly lower than that in the intact brain, in which more
than 60% of OPCs differentiated into mature oligodendrocytes
over the same time period. Interestingly, this maturation defect
in the injured area was relatively mild, when we considered the
entire OPC population, in which parenchymal OPCs predomi-
nate and the percentage of OPCs derived from the V-SVZ is small.
These data suggest that V-SVZ-derived OPCs/oligodendrocytes
are more susceptible to an inflammatory environment than are
parenchymal OPCs. Delayed AEPO treatment given for a dura-
tion of 2 weeks, but not for 3 days, could almost completely pre-
vent this maturation defect and neurological impairment. Taken
together, these findings indicate that EPO treatment enhances
OPC production in the V-SVZ and promotes the migration and
differentiation of V-SVZ-derived OPCs to supply new oligoden-
drocytes in the injured brain.
In summary, many studies support the idea that EPO enhances
neurogenesis and/or oligodendrogenesis at multiple steps after
brain insults (Figure 1). However, in most of these studies, EPO
was administered using the same protocols as those of the pre-
vious studies that demonstrated EPO-induced neuroprotection;
thus, the optimal dosage, timing, and duration of EPO treat-
ment for promoting regeneration have not been carefully inves-
tigated. Considering that regeneration is a continuous process
occurring over months to years, which is much longer than
the process of cell death, which mostly takes place during the
acute phase after insult, the optimal EPO treatment schedule
for efficient regeneration should be different from that used for
cytoprotection.
PERSPECTIVES
EPO and its derivatives appear to be promising drugs for pro-
moting neuron and oligodendrocyte regeneration by V-SVZ-
derived progenitors in various CNS disorders, as discussed above.
However, fundamental questions remain to be addressed. For
example, it is not known whether the V-SVZ-derived oligo-
dendrocytes induced by the EPO treatment are functionally
similar to those derived from parenchymal OPCs. In addi-
tion, the effect of EPO on neurogenesis and oligodendrogene-
sis in the primate V-SVZ remains to be studied. Furthermore,
FIGURE 1 | Effects of EPO treatment on the V-SVZ after brain injury.
Schematic representation of the effects of EPO treatment on
neurogenesis, oligodendrogenesis, and angiogenesis in the brain after
injury. EPO treatment enhances the proliferation of NSCs and neuronal
progenitors to increase the number of neuroblasts after injury, and
promotes recruitment of the neuroblasts to the injured area, where they
differentiate into mature neurons. EPO treatment increases the production
of migrating OPCs from the Olig2+/NG2+ transit-amplifying progenitors in
the V-SVZ, and promotes the differentiation of V-SVZ-derived OPCs into
oligodendrocytes in the injured area. The proliferation and differentiation of
the parenchymal OPCs are also enhanced by EPO. EPO also enhances
angiogenesis, which might be involved in the EPO-induced neurogenesis
and oligodendrogenesis after injury.
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the underlying mechanisms of EPO’s effects are still largely
unknown, especially those responsible for EPO’s effect on V-SVZ
oligodendrogenesis.
Notably, systemic rhEPO treatment has several potential risks,
including not only polycythemia and thrombosis, due to its
hematopoietic activity, but also hypertension due to increased
vascular smoothmuscle contraction (Vaziri et al., 1995; Miyashita
et al., 2004) and the promotion of malignant tumor growth by
enhanced tumor cell survival and angiogenesis (Yasuda et al.,
2003). Therefore, further studies to determine the mechanisms
of each effect of EPO and its derivatives should help guide the
development of appropriate treatments that specifically promote
neurogenesis and oligodendrogenesis without causing adverse
events.
AUTHOR CONTRIBUTIONS
Naoko Kaneko: conception and design, collection and assem-
bly of data, and manuscript writing, Eisuke Kako: collection and
assembly of data, Kazunobu Sawamoto: conception and design,
manuscript writing, and financial support
ACKNOWLEDGMENTS
We apologize to all whose work we could not cite because of
space limitations. We thank Dr. Hirohide Takebayashi (Niigata
University) for his careful and critical reading of our paper,
all of our collaborators for their contributions to the original
research and members of the Sawamoto Laboratory for their
valuable discussion. This work was supported by the Funding
Program for the Next Generation World-Leading Researchers (to
Kazunobu Sawamoto), JSPS KAKENHI Grant Number 23680041
and 25111727 (to Naoko Kaneko)
REFERENCES
Aguirre, A., Dupree, J. L., Mangin, J. M., and Gallo, V. (2007). A functional role for
EGFR signaling in myelination and remyelination. Nat. Neurosci. 10, 990–1002.
doi: 10.1038/nn1938
Azim, K., and Butt, A. M. (2011). GSK3beta negatively regulates oligoden-
drocyte differentiation and myelination in vivo. Glia 59, 540–553. doi:
10.1002/glia.21122
Banks, W. A., Jumbe, N. L., Farrell, C. L., Niehoff, M. L., and Heatherington,
A. C. (2004). Passage of erythropoietic agents across the blood-brain bar-
rier: a comparison of human and murine erythropoietin and the analog
darbepoetin alfa. Eur. J. Pharmacol. 505, 93–101. doi: 10.1016/j.ejphar.2004.
10.035
Belayev, L., Khoutorova, L., Zhao, W., Vigdorchik, A., Belayev, A., Busto, R., et al.
(2005). Neuroprotective effect of darbepoetin alfa, a novel recombinant ery-
thropoietic protein, in focal cerebral ischemia in rats. Stroke 36, 1071–1076. doi:
10.1161/01.STR.0000160753.36093.da
Belvindrah, R., Lazarini, F., and Lledo, P. M. (2009). Postnatal neurogenesis: from
neuroblast migration to neuronal integration. Rev. Neurosci. 20, 331–346. doi:
10.1515/REVNEURO.2009.20.5-6.331
Bernaudin, M., Bellail, A., Marti, H. H., Yvon, A., Vivien, D., Duchatelle, I.,
et al. (2000). Neurons and astrocytes express EPO mRNA: oxygen-sensing
mechanisms that involve the redox-state of the brain. Glia 30, 271–278. doi:
10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.0.CO;2-H
Bernaudin, M., Marti, H. H., Roussel, S., Divoux, D., Nouvelot, A., Mackenzie,
E. T., et al. (1999). A potential role for erythropoietin in focal permanent
cerebral ischemia in mice. J. Cereb. Blood Flow Metab. 19, 643–651. doi:
10.1097/00004647-199906000-00007
Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P., Fratelli, M., et al.
(2004). Erythropoietin mediates tissue protection through an erythropoietin
and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U.S.A. 101,
14907–14912. doi: 10.1073/pnas.0406491101
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C.,
et al. (2000). Erythropoietin crosses the blood-brain barrier to protect against
experimental brain injury. Proc. Natl. Acad. Sci. U.S.A. 97, 10526–10531. doi:
10.1073/pnas.97.19.10526
Carleton, A., Petreanu, L. T., Lansford, R., Alvarez-Buylla, A., and Lledo, P. M.
(2003). Becoming a new neuron in the adult olfactory bulb. Nat. Neurosci. 6,
507–518. doi: 10.1038/nn1048
Cayre, M., Courtes, S., Martineau, F., Giordano, M., Arnaud, K., Zamaron, A.,
et al. (2013). Netrin 1 contributes to vascular remodeling in the subventricu-
lar zone and promotes progenitor emigration after demyelination. Development
140, 3107–3117. doi: 10.1242/dev.092999
Chateauvieux, S., Grigorakaki, C., Morceau, F., Dicato, M., and Diederich, M.
(2011). Erythropoietin, erythropoiesis and beyond. Biochem. Pharmacol. 82,
1291–1303. doi: 10.1016/j.bcp.2011.06.045
Chen, Z. Y., Asavaritikrai, P., Prchal, J. T., and Noguchi, C. T. (2007).
Endogenous erythropoietin signaling is required for normal neural progeni-
tor cell proliferation. J. Biol. Chem. 282, 25875–25883. doi: 10.1074/jbc.M701
988200
Chikuma, M., Masuda, S., Kobayashi, T., Nagao, M., and Sasaki, R. (2000).
Tissue-specific regulation of erythropoietin production in the murine
kidney, brain, and uterus. Am. J. Physiol. Endocrinol. Metab. 279,
E1242–E1248.
Chin, K., Yu, X., Beleslin-Cokic, B., Liu, C., Shen, K., Mohrenweiser, H. W.,
et al. (2000). Production and processing of erythropoietin receptor tran-
scripts in brain. Brain Res. Mol. Brain Res. 81, 29–42. doi: 10.1016/S0169-
328X(00)00157-1
Chong, Z. Z., Kang, J. Q., and Maiese, K. (2002). Erythropoietin is a
novel vascular protectant through activation of Akt1 and mitochon-
drial modulation of cysteine proteases. Circulation 106, 2973–2979. doi:
10.1161/01.CIR.0000039103.58920.1F
Christie, K. J., and Turnley, A. M. (2012). Regulation of endogenous neural
stem/progenitor cells for neural repair-factors that promote neurogenesis and
gliogenesis in the normal and damaged brain. Front. Cell. Neurosci. 6:70. doi:
10.3389/fncel.2012.00070
Digicaylioglu, M., and Lipton, S. A. (2001). Erythropoietin-mediated neuropro-
tection involves cross-talk between Jak2 and NF-kappaB signalling cascades.
Nature 412, 641–647. doi: 10.1038/35088074
Ehrenreich, H., Degner, D., Meller, J., Brines, M., Behe, M.,
Hasselblatt, M., et al. (2004). Erythropoietin: a candidate com-
pound for neuroprotection in schizophrenia. Mol. Psychiatry 9,
42–54. doi: 10.1038/sj.mp.4001442
Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q. W., Coleman, T., Kreilgaard, M.,
et al. (2003). Asialoerythropoietin is a nonerythropoietic cytokine with broad
neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 100, 6741–6746.
doi: 10.1073/pnas.1031753100
Fan, X., Heijnen, C. J., van Der, K. M., Groenendaal, F., and van Bel, F. (2011).
Beneficial effect of erythropoietin on sensorimotor function and white mat-
ter after hypoxia-ischemia in neonatal mice. Pediatr. Res. 69, 56–61. doi:
10.1203/PDR.0b013e3181fcbef3
Fancy, S. P., Baranzini, S. E., Zhao, C., Yuk, D. I., Irvine, K. A., Kaing, S.,
et al. (2009). Dysregulation of the Wnt pathway inhibits timely myelination
and remyelination in the mammalian CNS. Genes Dev. 23, 1571–1585. doi:
10.1101/gad.1806309
Fancy, S. P., Harrington, E. P., Yuen, T. J., Silbereis, J. C., Zhao, C., Baranzini,
S. E., et al. (2011). Axin2 as regulatory and therapeutic target in newborn
brain injury and remyelination. Nat. Neurosci. 14, 1009–1016. doi: 10.1038/
nn.2855
Fancy, S. P., Zhao, C., and Franklin, R. J. (2004). Increased expression of
Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells respond-
ing to demyelination in the adult CNS. Mol. Cell. Neurosci. 27, 247–254. doi:
10.1016/j.mcn.2004.06.015
Franke, K., Gassmann, M., and Wielockx, B. (2013). Erythrocytosis: the HIF
pathway in control. Blood 122, 1122–1128. doi: 10.1182/blood-2013-01-478065
Fukuda, M. N., Sasaki, H., Lopez, L., and Fukuda, M. (1989). Survival of recom-
binant erythropoietin in the circulation: the role of carbohydrates. Blood 73,
84–89.
Gensert, J. M., and Goldman, J. E. (1997). Endogenous progenitors remyelinate
demyelinated axons in the adult CNS. Neuron 19, 197–203. doi: 10.1016/S0896-
6273(00)80359-1
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 235 | 7
Kaneko et al. Erythropoietin promotes neurogenesis and oligodendrogenesis
Ghezzi, P., and Brines, M. (2004). Erythropoietin as an antiapoptotic,
tissue-protective cytokine. Cell Death Differ. 11(Suppl. 1), S37–S44. doi:
10.1038/sj.cdd.4401450
Gonzalez, F. F., Larpthaveesarp, A., McQuillen, P., Derugin, N., Wendland, M.,
Spadafora, R., et al. (2013). Erythropoietin increases neurogenesis and oligo-
dendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke
44, 753–758. doi: 10.1161/STROKEAHA.111.000104
Gonzalez, F. F., McQuillen, P., Mu, D., Chang, Y., Wendland, M., Vexler, Z., et al.
(2007). Erythropoietin enhances long-term neuroprotection and neurogenesis
in neonatal stroke. Dev. Neurosci. 29, 321–330. doi: 10.1159/000105473
Gonzalez-Perez, O., and Alvarez-Buylla, A. (2011). Oligodendrogenesis in the sub-
ventricular zone and the role of epidermal growth factor. Brain Res. Rev. 67,
147–156. doi: 10.1016/j.brainresrev.2011.01.001
Grasso, G., Graziano, F., Sfacteria, A., Carletti, F., Meli, F., Maugeri, R., et al. (2009).
Neuroprotective effect of erythropoietin and darbepoetin alfa after experimen-
tal intracerebral hemorrhage. Neurosurgery 65, 763–769. discussion: 769–770.
doi: 10.1227/01.NEU.0000347475.73347.5F
Grasso, G., Sfacteria, A., Erbayraktar, S., Passalacqua, M., Meli, F., Gokmen, N.,
et al. (2006). Amelioration of spinal cord compressive injury by pharmacologi-
cal preconditioning with erythropoietin and a nonerythropoietic erythropoietin
derivative. J. Neurosurg. Spine 4, 310–318. doi: 10.3171/spi.2006.4.4.310
Greenwood, K., and Butt, A. M. (2003). Evidence that perinatal and adult NG2-
glia are not conventional oligodendrocyte progenitors and do not depend on
axons for their survival. Mol. Cell. Neurosci. 23, 544–558. doi: 10.1016/S1044-
7431(03)00176-3
Hack, M. A., Saghatelyan, A., de Chevigny, A., Pfeifer, A., Ashery-Padan, R.,
Lledo, P. M., et al. (2005). Neuronal fate determinants of adult olfactory bulb
neurogenesis. Nat. Neurosci. 8, 865–872. doi: 10.1038/nn1479
Hanazono, Y., Sasaki, K., Nitta, H., Yazaki, Y., and Hirai, H. (1995). Erythropoietin
induces tyrosine phosphorylation of the beta chain of the GM-CSF recep-
tor. Biochem. Biophys. Res. Commun. 208, 1060–1066. doi: 10.1006/bbrc.
1995.1442
Huang, J. K., Jarjour, A. A., Nait Oumesmar, B., Kerninon, C., Williams, A.,
Krezel, W., et al. (2011). Retinoid X receptor gamma signaling accelerates CNS
remyelination. Nat. Neurosci. 14, 45–53. doi: 10.1038/nn.2702
Ihrie, R. A., and Alvarez-Buylla, A. (2011). Lake-front property: a unique germi-
nal niche by the lateral ventricles of the adult brain. Neuron 70, 674–686. doi:
10.1016/j.neuron.2011.05.004
Imai, N., Higuchi, M., Kawamura, A., Tomonoh, K., Oh-Eda, M., Fujiwara, M.,
et al. (1990). Physicochemical and biological characterization of asialoery-
thropoietin. Suppressive effects of sialic acid in the expression of biological
activity of human erythropoietin in vitro. Eur. J. Biochem. 194, 457–462. doi:
10.1111/j.1432-1033.1990.tb15639.x
Imitola, J., Raddassi, K., Park, K. I., Mueller, F. J., Nieto, M., Teng, Y. D., et al. (2004).
Directedmigration of neural stem cells to sites of CNS injury by the stromal cell-
derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc. Natl. Acad. Sci.
U.S.A. 101, 18117–18122. doi: 10.1073/pnas.0408258102
Ivanova, A., Nakahira, E., Kagawa, T., Oba, A., Wada, T., Takebayashi, H., et al.
(2003). Evidence for a second wave of oligodendrogenesis in the postnatal
cerebral cortex of the mouse. J. Neurosci. Res. 73, 581–592. doi: 10.1002/
jnr.10717
Iwai, M., Cao, G., Yin, W., Stetler, R. A., Liu, J., and Chen, J. (2007). Erythropoietin
promotes neuronal replacement through revascularization and neurogen-
esis after neonatal hypoxia/ischemia in rats. Stroke 38, 2795–2803. doi:
10.1161/STROKEAHA.107.483008
Iwai, M., Stetler, R. A., Xing, J., Hu, X., Gao, Y., Zhang, W., et al. (2010).
Enhanced oligodendrogenesis and recovery of neurological function by erythro-
poietin after neonatal hypoxic/ischemic brain injury. Stroke 41, 1032–1037. doi:
10.1161/STROKEAHA.109.570325
Jablonska, B., Aguirre, A., Raymond, M., Szabo, G., Kitabatake, Y., Sailor, K. A.,
et al. (2010). Chordin-induced lineage plasticity of adult SVZ neuroblasts after
demyelination. Nat. Neurosci. 13, 541–550. doi: 10.1038/nn.2536
Jacobs, K., Shoemaker, C., Rudersdorf, R., Neill, S. D., Kaufman, R. J.,
Mufson, A., et al. (1985). Isolation and characterization of genomic and
cDNA clones of human erythropoietin. Nature 313, 806–810. doi: 10.1038/
313806a0
Jerndal, M., Forsberg, K., Sena, E. S., Macleod, M. R., O’collins, V. E., Linden,
T., et al. (2010). A systematic review and meta-analysis of erythropoietin
in experimental stroke. J. Cereb. Blood Flow Metab. 30, 961–968. doi:
10.1038/jcbfm.2009.267
Jubinsky, P. T., Krijanovski, O. I., Nathan, D. G., Tavernier, J., and Sieff, C. A. (1997).
The beta chain of the interleukin-3 receptor functionally associates with the
erythropoietin receptor. Blood 90, 1867–1873.
Juul, S. E., Anderson, D. K., Li, Y., and Christensen, R. D. (1998).
Erythropoietin and erythropoietin receptor in the developing human central
nervous system. Pediatr. Res. 43, 40–49. doi: 10.1203/00006450-199801000-
00007
Juul, S. E., McPherson, R. J., Farrell, F. X., Jolliffe, L., Ness, D. J., and Gleason,
C. A. (2004). Erytropoietin concentrations in cerebrospinal fluid of nonhuman
primates and fetal sheep following high-dose recombinant erythropoietin. Biol.
Neonate 85, 138–144. doi: 10.1159/000074970
Juul, S. E., Yachnis, A. T., Rojiani, A. M., and Christensen, R. D. (1999).
Immunohistochemical localization of erythropoietin and its receptor in
the developing human brain. Pediatr. Dev. Pathol. 2, 148–158. doi:
10.1007/s100249900103
Kadota, T., Shingo, T., Yasuhara, T., Tajiri, N., Kondo, A., Morimoto, T.,
et al. (2009). Continuous intraventricular infusion of erythropoietin exerts
neuroprotective/rescue effects upon Parkinson’s disease model of rats with
enhanced neurogenesis. Brain Res. 1254, 120–127. doi: 10.1016/j.brainres.2008.
11.094
Kako, E., Kaneko, N., Aoyama, M., Hida, H., Takebayashi, H., Ikenaka, K., et al.
(2012). Subventricular zone-derived oligodendrogenesis in injured neonatal
white matter in mice enhanced by a nonerythropoietic erythropoietin deriva-
tive. Stem Cells 30, 2234–2247. doi: 10.1002/stem.1202
Kato, S., Aoyama, M., Kakita, H., Hida, H., Kato, I., Ito, T., et al. (2011).
Endogenous erythropoietin from astrocyte protects the oligodendrocyte pre-
cursor cell against hypoxic and reoxygenation injury. J. Neurosci. Res. 89,
1566–1574. doi: 10.1002/jnr.22702
Kim, Y. J., and Jung, Y. W. (2010). Systemic injection of recombinant human
erythropoietin after focal cerebral ischemia enhances oligodendroglial and
endothelial progenitor cells in rat brain. Anat. Cell Biol. 43, 140–149. doi:
10.5115/acb.2010.43.2.140
King, V. R., Averill, S. A., Hewazy, D., Priestley, J. V., Torup, L., and Michael-Titus,
A. T. (2007). Erythropoietin and carbamylated erythropoietin are neuroprotec-
tive following spinal cord hemisection in the rat. Eur. J. Neurosci. 26, 90–100.
doi: 10.1111/j.1460-9568.2007.05635.x
Knabe, W., Knerlich, F., Washausen, S., Kietzmann, T., Siren, A. L., Brunnett,
G., et al. (2004). Expression patterns of erythropoietin and its receptor in the
developing midbrain. Anat. Embryol. 207, 503–512. doi: 10.1007/s00429-003-
0365-y
Kojima, T., Hirota, Y., Ema, M., Takahashi, S., Miyoshi, I., Okano, H., et al.
(2010). Subventricular zone-derived neural progenitor cells migrate along
a blood vessel scaffold toward the post-stroke striatum. Stem Cells 28,
545–554.
Kokovay, E., Goderie, S., Wang, Y., Lotz, S., Lin, G., Sun, Y., et al. (2010).
Adult SVZ lineage cells home to and leave the vascular niche via differ-
ential responses to SDF1/CXCR4 signaling. Cell Stem Cell 7, 163–173. doi:
10.1016/j.stem.2010.05.019
Kriegstein, A., and Alvarez-Buylla, A. (2009). The glial nature of embry-
onic and adult neural stem cells. Annu. Rev. Neurosci. 32, 149–184. doi:
10.1146/annurev.neuro.051508.135600
Lai, P. H., Everett, R., Wang, F. F., Arakawa, T., and Goldwasser, E. (1986).
Structural characterization of human erythropoietin. J. Biol. Chem. 261,
3116–3121.
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., et al. (2004).
Derivatives of erythropoietin that are tissue protective but not erythropoietic.
Science 305, 239–242. doi: 10.1126/science.1098313
Leker, R. R., Lasri, V., and Chernoguz, D. (2009). Growth factors improve neu-
rogenesis and outcome after focal cerebral ischemia. J. Neural Transm. 116,
1397–1402. doi: 10.1007/s00702-009-0329-3
Levison, S. W., and Goldman, J. E. (1993). Both oligodendrocytes and astrocytes
develop from progenitors in the subventricular zone of postnatal rat forebrain.
Neuron 10, 201–212. doi: 10.1016/0896-6273(93)90311-E
Li, L., Jiang, Q., Ding, G., Zhang, L., Zhang, Z. G., Li, Q., et al. (2009).
MRI identification of white matter reorganization enhanced by erythropoi-
etin treatment in a rat model of focal ischemia. Stroke 40, 936–941. doi:
10.1161/STROKEAHA.108.527713
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 235 | 8
Kaneko et al. Erythropoietin promotes neurogenesis and oligodendrogenesis
Li, Y., Lu, Z., Keogh, C. L., Yu, S. P., and Wei, L. (2007). Erythropoietin-
induced neurovascular protection, angiogenesis, and cerebral blood flow
restoration after focal ischemia in mice. J. Cereb. Blood Flow Metab. 27,
1043–1054. doi: 10.1038/sj.jcbfm.9600417
Lin, C. S., Lim, S. K., D’agati, V., and Costantini, F. (1996). Differential effects
of an erythropoietin receptor gene disruption on primitive and definitive
erythropoiesis. Genes Dev. 10, 154–164. doi: 10.1101/gad.10.2.154
Lin, F. K., Suggs, S., Lin, C. H., Browne, J. K., Smalling, R., Egrie, J. C., et al. (1985).
Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci.
U.S.A. 82, 7580–7584. doi: 10.1073/pnas.82.22.7580
Lindvall, O., and Kokaia, Z. (2010). Stem cells in human neurodegenera-
tive disorders–time for clinical translation? J. Clin. Invest. 120, 29–40. doi:
10.1172/JCI40543
Liu, C., Shen, K., Liu, Z., and Noguchi, C. T. (1997). Regulated human erythropoi-
etin receptor expression in mouse brain. J. Biol. Chem. 272, 32395–32400. doi:
10.1074/jbc.272.51.32395
Liu, W., Shen, Y., Plane, J. M., Pleasure, D. E., and Deng, W. (2011).
Neuroprotective potential of erythropoietin and its derivative carbamylated ery-
thropoietin in periventricular leukomalacia. Exp. Neurol. 230, 227–239. doi:
10.1016/j.expneurol.2011.04.021
Lois, C., and Alvarez-Buylla, A. (1994). Long-distance neuronal migration in the
adult mammalian brain. Science 264, 1145–1148. doi: 10.1126/science.8178174
Lombardero, M., Kovacs, K., and Scheithauer, B. W. (2011). Erythropoietin: a hor-
mone with multiple functions. Pathobiology 78, 41–53. doi: 10.1159/000322975
Luskin, M. B. (1993). Restricted proliferation and migration of postnatally gen-
erated neurons derived from the forebrain subventricular zone. Neuron 11,
173–189. doi: 10.1016/0896-6273(93)90281-U
Maiese, K., Chong, Z. Z., Shang, Y. C., and Wang, S. (2012). Erythropoietin:
new directions for the nervous system. Int. J. Mol. Sci. 13, 11102–11129. doi:
10.3390/ijms130911102
Maiese, K., Li, F., and Chong, Z. Z. (2004). Erythropoietin in the brain: can
the promise to protect be fulfilled? Trends Pharmacol. Sci. 25, 577–583. doi:
10.1016/j.tips.2004.09.006
Marti, H. H. (2004). Erythropoietin and the hypoxic brain. J. Exp. Biol. 207,
3233–3242. doi: 10.1242/jeb.01049
Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Digicaylioglu, M., Henn,
V., et al. (1996). Erythropoietin gene expression in human, monkey and murine
brain. Eur. J. Neurosci. 8, 666–676. doi: 10.1111/j.1460-9568.1996.tb01252.x
Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M., and Sasaki, R. (1994).
A novel site of erythropoietin production. Oxygen-dependent production in
cultured rat astrocytes. J. Biol. Chem. 269, 19488–19493.
Menn, B., Garcia-Verdugo, J. M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D., and
Alvarez-Buylla, A. (2006). Origin of oligodendrocytes in the subventricular zone
of the adult brain. J. Neurosci. 26, 7907–7918. doi: 10.1523/JNEUROSCI.1299-
06.2006
Mi, S., Lee, X., Hu, Y., Ji, B., Shao, Z., Yang, W., et al. (2011). Death receptor 6
negatively regulates oligodendrocyte survival, maturation andmyelination.Nat.
Med. 17, 816–821. doi: 10.1038/nm.2373
Ming, G. L., and Song, H. (2011). Adult neurogenesis in the mammalian
brain: significant answers and significant questions. Neuron 70, 687–702. doi:
10.1016/j.neuron.2011.05.001
Mirzadeh, Z., Merkle, F. T., Soriano-Navarro, M., Garcia-Verdugo, J. M., and
Alvarez-Buylla, A. (2008). Neural stem cells confer unique pinwheel architec-
ture to the ventricular surface in neurogenic regions of the adult brain.Cell Stem
Cell 3, 265–278. doi: 10.1016/j.stem.2008.07.004
Miyashita, K., Tojo, A., Kimura, K., Goto, A., Omata, M., Nishiyama, K., et al.
(2004). Blood pressure response to erythropoietin injection in hemodialysis and
predialysis patients. Hypertens. Res. 27, 79–84. doi: 10.1291/hypres.27.79
Mizuno, K., Hida, H., Masuda, T., Nishino, H., and Togari, H. (2008). Pretreatment
with low doses of erythropoietin ameliorates brain damage in periventricu-
lar leukomalacia by targeting late oligodendrocyte progenitors: a rat model.
Neonatology 94, 255–266. doi: 10.1159/000151644
Montero, M., Poulsen, F. R., Noraberg, J., Kirkeby, A., van Beek, J., Leist, M., et al.
(2007). Comparison of neuroprotective effects of erythropoietin (EPO) and car-
bamylerythropoietin (CEPO) against ischemia-like oxygen-glucose deprivation
(OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures. Exp.
Neurol. 204, 106–117. doi: 10.1016/j.expneurol.2006.09.026
Morishita, E., Masuda, S., Nagao, M., Yasuda, Y., and Sasaki, R. (1997).
Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical
neurons, and erythropoietin prevents in vitro glutamate-induced neuronal
death. Neuroscience 76, 105–116. doi: 10.1016/S0306-4522(96)00306-5
Nadam, J., Navarro, F., Sanchez, P., Moulin, C., Georges, B., Laglaine, A., et al.
(2007). Neuroprotective effects of erythropoietin in the rat hippocampus
after pilocarpine-induced status epilepticus. Neurobiol. Dis. 25, 412–426. doi:
10.1016/j.nbd.2006.10.009
Nagai, A., Nakagawa, E., Choi, H. B., Hatori, K., Kobayashi, S., and Kim, S. U.
(2001). Erythropoietin and erythropoietin receptors in human CNS neurons,
astrocytes, microglia, and oligodendrocytes grown in culture. J. Neuropathol.
Exp. Neurol. 60, 386–392.
Nait-Oumesmar, B., Decker, L., Lachapelle, F., Avellana-Adalid, V., Bachelin, C.,
and Baron-Van Evercooren, A. (1999). Progenitor cells of the adult mouse
subventricular zone proliferate, migrate and differentiate into oligodendro-
cytes after demyelination. Eur. J. Neurosci. 11, 4357–4366. doi: 10.1046/j.1460-
9568.1999.00873.x
Nait-Oumesmar, B., Picard-Riera, N., Kerninon, C., and Baron-Van Evercooren,
A. (2008). The role of SVZ-derived neural precursors in demyelinating dis-
eases: from animal models to multiple sclerosis. J. Neurol. Sci. 265, 26–31. doi:
10.1016/j.jns.2007.09.032
Nait-Oumesmar, B., Picard-Riera, N., Kerninon, C., Decker, L., Seilhean, D.,
Hoglinger, G. U., et al. (2007). Activation of the subventricular zone in mul-
tiple sclerosis: evidence for early glial progenitors. Proc. Natl. Acad. Sci. U.S.A.
104, 4694–4699. doi: 10.1073/pnas.0606835104
Nakaguchi, K., Masuda, H., Kaneko, N., and Sawamoto, K. (2011). Strategies for
regenerating striatal neurons in the adult brain by using endogenous neural
stem cells. Neurol. Res. Int. 2011, 898012. doi: 10.1155/2011/898012
Nishiyama, A., Watanabe, M., Yang, Z., and Bu, J. (2002). Identity, distribution,
and development of polydendrocytes: NG2-expressing glial cells. J. Neurocytol.
31, 437–455. doi: 10.1023/A:1025783412651
Noguchi, C. T., Asavaritikrai, P., Teng, R., and Jia, Y. (2007). Role of ery-
thropoietin in the brain. Crit. Rev. Oncol. Hematol. 64, 159–171. doi:
10.1016/j.critrevonc.2007.03.001
Ohab, J. J., Fleming, S., Blesch, A., and Carmichael, S. T. (2006). A neurovas-
cular niche for neurogenesis after stroke. J. Neurosci. 26, 13007–13016. doi:
10.1523/JNEUROSCI.4323-06.2006
Patel, J. R., McCandless, E. E., Dorsey, D., and Klein, R. S. (2010). CXCR4 pro-
motes differentiation of oligodendrocyte progenitors and remyelination. Proc.
Natl. Acad. Sci. U.S.A. 107, 11062–11067. doi: 10.1073/pnas.1006301107
Petreanu, L., and Alvarez-Buylla, A. (2002). Maturation and death of adult-
born olfactory bulb granule neurons: role of olfaction. J. Neurosci. 22,
6106–6113. doi: 20026588
Picard-Riera, N., Decker, L., Delarasse, C., Goude, K., Nait-Oumesmar, B.,
Liblau, R., et al. (2002). Experimental autoimmune encephalomyelitis mobi-
lizes neural progenitors from the subventricular zone to undergo oligoden-
drogenesis in adult mice. Proc. Natl. Acad. Sci. U.S.A. 99, 13211–13216. doi:
10.1073/pnas.192314199
Quelle, F. W., Wang, D., Nosaka, T., Thierfelder, W. E., Stravopodis, D., Weinstein,
Y., et al. (1996). Erythropoietin induces activation of Stat5 through association
with specific tyrosines on the receptor that are not required for a mitogenic
response. Mol. Cell. Biol. 16, 1622–1631.
Reynolds, R., Dawson,M., Papadopoulos, D., Polito, A., Di Bello, I. C., Pham-Dinh,
D., et al. (2002). The response of NG2-expressing oligodendrocyte progeni-
tors to demyelination in MOG-EAE and MS. J. Neurocytol. 31, 523–536. doi:
10.1023/A:1025747832215
Robin, A. M., Zhang, Z. G., Wang, L., Zhang, R. L., Katakowski, M., Zhang, L.,
et al. (2006). Stromal cell-derived factor 1alpha mediates neural progenitor cell
motility after focal cerebral ischemia. J. Cereb. Blood Flow Metab. 26, 125–134.
doi: 10.1038/sj.jcbfm.9600172
Sanchez, P. E., Navarro, F. P., Fares, R. P., Nadam, J., Georges, B., Moulin, C., et al.
(2009). Erythropoietin receptor expression is concordant with erythropoietin
but not with common beta chain expression in the rat brain throughout the life
span. J. Comp. Neurol. 514, 403–414. doi: 10.1002/cne.22020
Savino, C., Pedotti, R., Baggi, F., Ubiali, F., Gallo, B., Nava, S., et al. (2006). Delayed
administration of erythropoietin and its non-erythropoietic derivatives ame-
liorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 172,
27–37. doi: 10.1016/j.jneuroim.2005.10.016
Seymen, P., Aytac, E., Esen, F., Tel, C., Demir, F., Genc, H., et al. (2013). Darbepoetin
alpha ameliorates neuronal damage in a rat model of acute ethanol intoxication.
Int. J. Neurosci. 123, 99–103. doi: 10.3109/00207454.2012.738732
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 235 | 9
Kaneko et al. Erythropoietin promotes neurogenesis and oligodendrogenesis
Shen, Q., Wang, Y., Kokovay, E., Lin, G., Chuang, S. M., Goderie, S. K., et al. (2008).
Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-
cell interactions. Cell Stem Cell 3, 289–300. doi: 10.1016/j.stem.2008.07.026
Shingo, T., Sorokan, S. T., Shimazaki, T., and Weiss, S. (2001). Erythropoietin
regulates the in vitro and in vivo production of neuronal progen-
itors by mammalian forebrain neural stem cells. J. Neurosci. 21,
9733–9743.
Siren, A. L., Fasshauer, T., Bartels, C., and Ehrenreich, H. (2009). Therapeutic
potential of erythropoietin and its structural or functional variants in the
nervous system. Neurotherapeutics 6, 108–127. doi: 10.1016/j.nurt.2008.10.041
Siren, A. L., Knerlich, F., Poser, W., Gleiter, C. H., Bruck, W., and
Ehrenreich, H. (2001). Erythropoietin and erythropoietin recep-
tor in human ischemic/hypoxic brain. Acta Neuropathol. 101,
271–276. doi: 10.1007/s004010000297
Snapyan, M., Lemasson, M., Brill, M. S., Blais, M., Massouh, M., Ninkovic, J., et al.
(2009). Vasculature guides migrating neuronal precursors in the adult mam-
malian forebrain via brain-derived neurotrophic factor signaling. J. Neurosci.
29, 4172–4188. doi: 10.1523/JNEUROSCI.4956-08.2009
Stallcup, W. B., and Beasley, L. (1987). Bipotential glial precursor cells
of the optic nerve express the NG2 proteoglycan. J. Neurosci. 7,
2737–2744.
Sugawa, M., Sakurai, Y., Ishikawa-Ieda, Y., Suzuki, H., and Asou, H. (2002).
Effects of erythropoietin on glial cell development; oligodendrocyte maturation
and astrocyte proliferation. Neurosci. Res. 44, 391–403. doi: 10.1016/S0168-
0102(02)00161-X
Suzuki, N., Ohneda, O., Takahashi, S., Higuchi, M., Mukai, H. Y., Nakahata,
T., et al. (2002). Erythroid-specific expression of the erythropoietin recep-
tor rescued its null mutant mice from lethality. Blood 100, 2279–2288. doi:
10.1182/blood-2002-01-0124
Suzuki, S. O., and Goldman, J. E. (2003). Multiple cell populations in the
early postnatal subventricular zone take distinct migratory pathways: a
dynamic study of glial and neuronal progenitor migration. J. Neurosci. 23,
4240–4250.
Tan, C. C., Eckardt, K. U., Firth, J. D., and Ratcliffe, P. J. (1992). Feedback modu-
lation of renal and hepatic erythropoietin mRNA in response to graded anemia
and hypoxia. Am. J. Physiol. 263, F474–F481.
Tavazoie, M., Van der Veken, L., Silva-Vargas, V., Louissaint, M., Colonna, L., Zaidi,
B., et al. (2008). A specialized vascular niche for adult neural stem cells. Cell
Stem Cell 3, 279–288. doi: 10.1016/j.stem.2008.07.025
Tsai, P. T., Ohab, J. J., Kertesz, N., Groszer, M., Matter, C., Gao, J., et al. (2006). A
critical role of erythropoietin receptor in neurogenesis and post-stroke recovery.
J. Neurosci. 26, 1269–1274. doi: 10.1523/JNEUROSCI.4480-05.2006
Um, M., Gross, A. W., and Lodish, H. F. (2007). A “classical” homodimeric ery-
thropoietin receptor is essential for the antiapoptotic effects of erythropoietin
on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells.
Cell. Signal. 19, 634–645. doi: 10.1016/j.cellsig.2006.08.014
van der Kooij, M. A., Groenendaal, F., Kavelaars, A., Heijnen, C. J., and van Bel, F.
(2008). Neuroprotective properties and mechanisms of erythropoietin in vitro
and in vivo experimental models for hypoxia/ischemia. Brain Res. Rev. 59,
22–33. doi: 10.1016/j.brainresrev.2008.04.007
Vaziri, N. D., Zhou, X. J., Smith, J., Oveisi, F., Baldwin, K., and Purdy, R. E. (1995).
In vivo and in vitro pressor effects of erythropoietin in rats. Am. J. Physiol. 269,
F838–F845.
Villa, P., van Beek, J., Larsen, A. K., Gerwien, J., Christensen, S., Cerami, A.,
et al. (2007). Reduced functional deficits, neuroinflammation, and secondary
tissue damage after treatment of stroke by nonerythropoietic erythropoietin
derivatives. J. Cereb. Blood Flow Metab. 27, 552–563. doi: 10.1038/sj.jcbfm.
9600370
Vitellaro-Zuccarello, L., Mazzetti, S., Madaschi, L., Bosisio, P., Gorio, A.,
and De Biasi, S. (2007). Erythropoietin-mediated preservation of the
white matter in rat spinal cord injury. Neuroscience 144, 865–877. doi:
10.1016/j.neuroscience.2006.10.023
Wang, L., Chopp, M., Gregg, S. R., Zhang, R. L., Teng, H., Jiang, A., et al.
(2008). Neural progenitor cells treated with EPO induce angiogenesis through
the production of VEGF. J. Cereb. Blood Flow Metab. 28, 1361–1368. doi:
10.1038/jcbfm.2008.32
Wang, L., Zhang, Z. G., Gregg, S. R., Zhang, R. L., Jiao, Z., Letourneau,
Y., et al. (2007a). The Sonic hedgehog pathway mediates carbamylated
erythropoietin-enhanced proliferation and differentiation of adult neural
progenitor cells. J. Biol. Chem. 282, 32462–32470. doi: 10.1074/jbc.M706
880200
Wang, Y., Zhang, Z. G., Rhodes, K., Renzi, M., Zhang, R. L., Kapke, A., et al.
(2007b). Post-ischemic treatment with erythropoietin or carbamylated ery-
thropoietin reduces infarction and improves neurological outcome in a rat
model of focal cerebral ischemia. Br. J. Pharmacol. 151, 1377–1384. doi:
10.1038/sj.bjp.0707285
Wang, L., Zhang, Z. G., Zhang, R. L., Gregg, S. R., Hozeska-Solgot, A.,
Letourneau, Y., et al. (2006a). Matrix metalloproteinase 2 (MMP2) and MMP9
secreted by erythropoietin-activated endothelial cells promote neural progeni-
tor cell migration. J. Neurosci. 26, 5996–6003. doi: 10.1523/JNEUROSCI.5380-
05.2006
Wang, L., Zhang, Z. G., Zhang, R. L., Jiao, Z. X., Wang, Y., Pourabdollah-Nejad, D.
S., et al. (2006b). Neurogenin 1 mediates erythropoietin enhanced differentia-
tion of adult neural progenitor cells. J. Cereb. Blood Flow Metab. 26, 556–564.
doi: 10.1038/sj.jcbfm.9600215
Wang, L., Zhang, Z., Wang, Y., Zhang, R., and Chopp, M. (2004a). Treatment
of stroke with erythropoietin enhances neurogenesis and angiogenesis
and improves neurological function in rats. Stroke 35, 1732–1737. doi:
10.1161/01.STR.0000132196.49028.a4
Wang, X., Zhu, C., Wang, X., Gerwien, J. G., Schrattenholz, A., Sandberg, M., et al.
(2004b). The nonerythropoietic asialoerythropoietin protects against neonatal
hypoxia-ischemia as potently as erythropoietin. J. Neurochem. 91, 900–910. doi:
10.1111/j.1471-4159.2004.02769.x
Wang, Y., Cooke, M. J., Morshead, C. M., and Shoichet, M. S. (2012).
Hydrogel delivery of erythropoietin to the brain for endogenous stem
cell stimulation after stroke injury. Biomaterials 33, 2681–2692. doi:
10.1016/j.biomaterials.2011.12.031
Whitman, M. C., Fan, W., Rela, L., Rodriguez-Gil, D. J., and Greer, C. A. (2009).
Blood vessels form amigratory scaffold in the rostral migratory stream. J. Comp.
Neurol. 516, 94–104. doi: 10.1002/cne.22093
Wu, H., Liu, X., Jaenisch, R., and Lodish, H. F. (1995). Generation of commit-
ted erythroid BFU-E and CFU-E progenitors does not require erythropoietin
or the erythropoietin receptor. Cell 83, 59–67. doi: 10.1016/0092-8674(95)
90234-1
Xenocostas, A., Cheung, W. K., Farrell, F., Zakszewski, C., Kelley, M., Lutynski,
A., et al. (2005). The pharmacokinetics of erythropoietin in the cere-
brospinal fluid after intravenous administration of recombinant human ery-
thropoietin. Eur. J. Clin. Pharmacol. 61, 189–195. doi: 10.1007/s00228-005-
0896-7
Xiong, Y., Mahmood, A., Zhang, Y., Meng, Y., Zhang, Z. G., Qu, C., et al. (2011).
Effects of posttraumatic carbamylated erythropoietin therapy on reducing
lesion volume and hippocampal cell loss, enhancing angiogenesis and neuro-
genesis, and improving functional outcome in rats following traumatic brain
injury. J. Neurosurg. 114, 549–559. doi: 10.3171/2010.10.JNS10925
Yamashita, T., Ninomiya, M., Hernandez Acosta, P., Garcia-Verdugo, J. M.,
Sunabori, T., Sakaguchi, M., et al. (2006). Subventricular zone-derived neu-
roblasts migrate and differentiate into mature neurons in the post-stroke
adult striatum. J. Neurosci. 26, 6627–6636. doi: 10.1523/JNEUROSCI.0149-
06.2006
Yang, Y., and Rosenberg, G. A. (2011). Blood-brain barrier breakdown in
acute and chronic cerebrovascular disease. Stroke 42, 3323–3328. doi:
10.1161/STROKEAHA.110.608257
Yasuda, Y., Fujita, Y., Matsuo, T., Koinuma, S., Hara, S., Tazaki, A., et al. (2003).
Erythropoietin regulates tumour growth of humanmalignancies.Carcinogenesis
24, 1021–1029. doi: 10.1093/carcin/bgg060
Yoshikawa, G., Momiyama, T., Oya, S., Takai, K., Tanaka, J., Higashiyama, S.,
et al. (2010). Induction of striatal neurogenesis and generation of region-
specific functional mature neurons after ischemia by growth factors. Laboratory
investigation. J. Neurosurg. 113, 835–850. doi: 10.3171/2010.2.JNS09989
Yu, X., Shacka, J. J., Eells, J. B., Suarez-Quian, C., Przygodzki, R. M., Beleslin-Cokic,
B., et al. (2002). Erythropoietin receptor signalling is required for normal brain
development. Development 129, 505–516.
Zhang, J., Li, Y., Cui, Y., Chen, J., Lu, M., Elias, S. B., et al. (2005). Erythropoietin
treatment improves neurological functional recovery in EAE mice. Brain Res.
1034, 34–39. doi: 10.1016/j.brainres.2004.11.036
Zhang, L., Chopp, M., Zhang, R. L., Wang, L., Zhang, J., Wang, Y., et al. (2010).
Erythropoietin amplifies stroke-induced oligodendrogenesis in the rat. PLoS
ONE 5:e11016. doi: 10.1371/journal.pone.0011016
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 235 | 10
Kaneko et al. Erythropoietin promotes neurogenesis and oligodendrogenesis
Zhang, Y., Chopp, M., Mahmood, A., Meng, Y., Qu, C., and Xiong, Y.
(2012). Impact of inhibition of erythropoietin treatment-mediated neuro-
genesis in the dentate gyrus of the hippocampus on restoration of spa-
tial learning after traumatic brain injury. Exp. Neurol. 235, 336–344. doi:
10.1016/j.expneurol.2012.02.015
Zhao, W., Kitidis, C., Fleming, M. D., Lodish, H. F., and Ghaffari, S. (2006).
Erythropoietin stimulates phosphorylation and activation of GATA-1 via the
PI3-kinase/AKT signaling pathway. Blood 107, 907–915. doi: 10.1182/blood-
2005-06-2516
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 03 September 2013; accepted: 08 November 2013; published online: 27
November 2013.
Citation: Kaneko N, Kako E and Sawamoto K (2013) Enhancement of ventricular-
subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin
and its derivatives. Front. Cell. Neurosci. 7:235. doi: 10.3389/fncel.2013.00235
This article was submitted to the journal Frontiers in Cellular Neuroscience.
Copyright © 2013 Kaneko, Kako and Sawamoto. This is an open-access arti-
cle distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, pro-
vided the original author(s) or licensor are credited and that the original publi-
cation in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Cellular Neuroscience www.frontiersin.org November 2013 | Volume 7 | Article 235 | 11
